ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Clinical trial NCT05446298 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05446298
Sponsor: OncoC4, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Cancer High Grade Serous Adenocarcinoma of Ovary Primary Peritoneal Carcinoma Fallopian Tube Cancer

Start date: 2022-12-22
Primary completion: 2026-08-30
Enrollment: 58

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.